ClinicalTrials.gg
Active, not recruitingNCT06527794RHYTHM-BUpdated Nov 16, 2026

Remote Hypertension Management for Black Patients

An interventional study of RHYTHM (Remote Hypertension Tracking Help Management) and Enhanced usual care (UC) in Uncontrolled Hypertension, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Health services research

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
864
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hypertension by Wake Forest University Health Sciences — 4 open to participants now, 7 under way, none of them phase 3. Hypertension · Wake Forest University Health Sciences.

Enrollment
2nd of 20
864 · median 41
Started
2024
with 3 others
No phase
17 of 25
3 open now
Registered
21st of 25
by date

Among the 25 studies in Hypertension by Wake Forest University Health Sciences, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, and was the 21st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 25 studies in Hypertension by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypertension by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This study will compare two approaches for managing hypertension in Black patients with uncontrolled blood pressure (BP). One approach will include home BP telemonitoring supported by a pharmacist and a community health worker. The other approach will include usual clinic-based care along with a home BP monitor and routine care.

Read the detailed description

This study is a pragmatic effectiveness-implementation hybrid type 2 trial with two study arms. One arm will include home BP telemonitoring supported by a pharmacist and a community health worker providing centralized self-management support. The other arm will include enhanced usual clinic-based care with a home BP monitor and routine care from providers trained on evidence-based guidelines.

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

Keywords

  • high blood pressure
  • African-American population
  • remote blood pressure monitoring
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Black or African American race
  • Hypertension diagnosis
  • aged 21 to 85 years
  • Uncontrolled blood pressure as defined by [a] most recent SBP ≥140 mmHg and an additional SBP≥140 mmHg within the past 12 months in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or [b] most recent SBP>160mmHg in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or [c] referral by PCP for uncontrolled hypertension with at least one documented SBP≥140 mmHg (in clinic or at home) in the past 12 months; and (v) primary care provided at a participating clinic.
  • Able to speak English
  • Primary care provided at a participating clinic

Exclusion criteria

Exclusion Criteria:

  • currently pregnant or planning to get pregnant during the study period
  • residence in a long-term care facility, hospice or with a terminal illness with less than 1 year as determined by the Primary Care Physician or study team. Stable chronic illness such as compensated cirrhosis, , congestive heart failure etc. will not be excluded.
  • estimated (eGFR) \<30 ml/min or on dialysis. Patients with a functioning kidney transplant will not be excluded.
  • inability to provide or participate in study procedures. For example, conditions that limit ability to participate in phone visits or check BPs in at least one arm.
  • currently participating in another BP management program.
  • plan to move out of the area within the next 12 months.
  • Hispanic ethnicity.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
864 participants (actual)

Study arms

  • Experimental
    RHYTHM (Remote Hypertension Tracking Help Management)

    home blood pressure telemonitoring with remote medication management and social support, lifestyle education and connection to community resources to address social needs

    Behavioral: RHYTHM (Remote Hypertension Tracking Help Management)

  • Experimental
    Enhanced usual care (UC)

    standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home

    Behavioral: Enhanced usual care (UC)

Interventions

  • BehavioralRHYTHM (Remote Hypertension Tracking Help Management)

    Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners

  • BehavioralEnhanced usual care (UC)

    All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.

06

What researchers measure

Primary outcomes

  1. Blood pressure control - Percent of patients achieving BP control (i.e., Systolic BP<130mmHg) - Month 12

    Percent of patients achieving BP control (i.e., SBP\<130mmHg)

    Time frame: Month 12

Secondary outcomes

  1. Blood pressure control - Percent of patients achieving BP control (i.e., Systolic BP<130mmHg) - Baseline

    Percent of patients achieving BP control (i.e., SBP\<130mmHg)

    Time frame: Baseline

  2. Blood pressure control - Percent of patients achieving BP control (i.e., Systolic BP<130mmHg) - Month 6

    Percent of patients achieving BP control (i.e., SBP\<130mmHg)

    Time frame: Month 6

  3. Blood pressure control - Percent of patients achieving BP control (i.e., Systolic BP<130mmHg) - Month 18

    Percent of patients achieving BP control (i.e., SBP\<130mmHg)

    Time frame: Month 18

  4. Systolic blood pressure (mmHg) - Baseline

    Mean SBP (mmHg)

    Time frame: Baseline

  5. Systolic blood pressure (mmHg) - Month 6

    Mean SBP (mmHg)

    Time frame: Month 6

  6. Systolic blood pressure (mmHg) - Month 12

    Mean SBP (mmHg)

    Time frame: Month 12

  7. Systolic blood pressure (mmHg) - Month 18

    Mean SBP (mmHg)

    Time frame: Month 18

  8. Self-Management - Hypertension Self-Care Profile Score - Baseline

    The hypertension self-care profile score encompassed self-care behaviors crucial to control blood pressure - Includes 3 scales (Behavior, Motivation, Self-efficacy) 20 items each that can be used together or independently. The Behavior scale assesses participant's self-care behaviors on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-care behavior. The Motivation scale assesses participant's self-care motivation on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-care motivation. The Self-efficacy scale assesses participant's self-care efficacy on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-efficacy. Higher scores indicate better self care behaviors - range from 60-240.

    Time frame: Baseline

  9. Self-Management - Hypertension Self-Care Profile Score - Month 12

    The hypertension self-care profile score encompassed self-care behaviors crucial to control blood pressure - Includes 3 scales (Behavior, Motivation, Self-efficacy) 20 items each that can be used together or independently. The Behavior scale assesses participant's self-care behaviors on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-care behavior. The Motivation scale assesses participant's self-care motivation on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-care motivation. The Self-efficacy scale assesses participant's self-care efficacy on a 4-point Likert scale. Mean scores range from 1-4 with higher scores indicating higher levels of self-efficacy. Higher scores indicate better self care behaviors - range from 60-240.

    Time frame: Month 12

  10. Medication adherence - Hill-Bone medication adherence scale survey score - Baseline

    Hill-Bone medication adherence scale survey - 14-item Hill-Bone Compliance Scale uses a 4-point Likert scale. Score range from 14-56. Higher scores indicates poorer adherence.

    Time frame: Baseline

  11. Medication adherence - Hill-Bone medication adherence scale survey score - Month 12

    Hill-Bone medication adherence scale survey - 14-item Hill-Bone Compliance Scale uses a 4-point Likert scale. Score range from 14-56. Higher scores indicates poorer adherence.

    Time frame: Month 12

  12. Patient assessment of chronic illness care (PACIC) survey score - Baseline

    The Patient assessment of chronic illness care (PACIC) survey assess implementation of the chronic care model from the patient perspective. The PACIC includes five subscales addressing specific domains: (1) patient activation; (2) delivery system design/decision support; (3) goal setting/tailoring; (4) problem solving/contextual counselling; and (5) follow-up/coordination. Patients rated care received from their healthcare team (e.g., physicians, nurses, physiotherapists, occupational therapists, social workers) during the past 6-months using a 5-point Likert scale (1 = 'never' to 5 = 'always'). Total and subscale scores (i.e., summed items completed within that scale) are averaged across items.

    Time frame: Baseline

  13. Patient assessment of chronic illness care (PACIC) survey score - Month 12

    The Patient assessment of chronic illness care (PACIC) survey assess implementation of the chronic care model from the patient perspective. The PACIC includes five subscales addressing specific domains: (1) patient activation; (2) delivery system design/decision support; (3) goal setting/tailoring; (4) problem solving/contextual counselling; and (5) follow-up/coordination. Patients rated care received from their healthcare team (e.g., physicians, nurses, physiotherapists, occupational therapists, social workers) during the past 6-months using a 5-point Likert scale (1 = 'never' to 5 = 'always'). Total and subscale scores (i.e., summed items completed within that scale) are averaged across items.

    Time frame: Month 12

  14. 20-Item Short Form Health Survey (SF-20) - Baseline

    The SF-36 Total/Global/Overall Score, a global measure of health-related quality of life - scores range from 0-100 with higher scores denoting better quality of life

    Time frame: Baseline

  15. 20-Item Short Form Health Survey (SF-20) - Month 12

    The SF-36 Total/Global/Overall Score, a global measure of health-related quality of life - scores range from 0-100 with higher scores denoting better quality of life

    Time frame: Month 12

  16. Healthcare Utilization - Number of Acute Care Days - Baseline

    Total days spent in an emergency department, inpatient hospital, or observation unit; number of physician office visits.

    Time frame: Baseline

  17. Healthcare Utilization - Number of Acute Care Days - Month 12

    Total days spent in an emergency department, inpatient hospital, or observation unit; number of physician office visits.

    Time frame: Month 12

  18. Healthcare Utilization - Number of Acute Care Days - Month 24

    Total days spent in an emergency department, inpatient hospital, or observation unit; number of physician office visits.

    Time frame: Month 24

Other outcomes

  1. Therapeutic intensification Score

    The therapeutic intensity score is a number that reflects the number of medications and the percent of maximal dose of each medication. Numeric range 0-5.

    Time frame: Month 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Patient-Centered Outcomes Research Institute (PCORI) Data Management and Data Sharing Policy, will prepare a Full Data Package (analyzable data set, full protocol, metadata, data dictionary, full statistical analysis plan and analytic code) for access by third parties. Per PCORI policy, the Full Data Package will be maintained at Atrium Health for 7 years, unless required by PCORI to be deposited in a separate repository.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The Policy calls for maintenance of the Full Data Package for seven (7) years following acceptance by PCORI of the Final Research Report. In that time, PCORI may provide funds for the deposition of the Full Data Package to the PCORI-designated repository in circumstances where PCORI requests such deposition (e.g., due to PCORI estimate of high importance of research project findings or external research request).

Access criteria: Individual investigators or teams of investigators seeking access to data from PCORI-funded studies must complete and submit a data request form to the PCORI-designated repository. There are no categorical restrictions on what types of individuals or entities may request to access the PCORI Awardee research data. Data requestors will be evaluated for their overall qualifications and experience (e.g., across a proposed team of specified individuals) to achieve the stated research purpose underlying the data request.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Oct 2027, 34 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 34 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2028 → Oct 2027, last on Nov 16, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2028 → Nov 2028, last on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Oct 2027was Sep 2028
CompletionEst.
Nov 2028was Sep 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Primary completion
Sep 2028→Oct 2027
moved 2 times, Nov 12, 2026 – Nov 16, 2026
Study completion
Sep 2028→Nov 2028
moved 2 times, Nov 12, 2026 – Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Primary completion Sep 19, 2026→Oct 2027
    Study completion Mar 2027→Nov 2028
  2. Nov 12, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 2028→Sep 19, 2026 (now actual)
    Study completion Sep 2028→Mar 2027
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06527794
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Dec 13, 2024
Primary completion
Oct 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Yhenneko J. Taylor, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion